Distribution of Early Structural Lung Changes due to Cystic Fibrosis Detected with Chest Computed Tomography - 22/06/13
Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) Study Group∗∗
Abstract |
Objective |
To examine the distribution of early structural lung changes in clinically stable infants and young children with cystic fibrosis using chest computed tomography (CT).
Study design |
This cross-sectional study included 62 children aged 1-6 years with volume-controlled volumetric chest CT scans performed under general anesthesia as part of an early surveillance program. Each lobe was scored for presence and extent of bronchiectasis, mucus plugging, and air trapping using a semiquantitative score. The topographic distribution of structural abnormalities was evaluated by comparing the presence and extent of abnormalities in different lung regions and examining relationships between components.
Results |
Although bronchiectasis was most common in the right upper lobe, overall changes in lung structure were not more common or more extensive in the upper lobes. Rather, bronchiectasis was more common in the right lung (right lung 0.95, left lung 0.68, P = .003), and mucus plugging (upper 0.41, middle 0.41, lower 0.72, P = .028) and air trapping (upper 0.79, middle 0.48, lower 0.96, P < .001) were more common in the lower lobes. The extents of bronchiectasis (P < .001) and air trapping (P = .011) were greater in the right lung. Scans with bronchiectasis were also more likely to have coexisting mucus plugging (P = .008) and air trapping (P < .001).
Conclusion |
Early structural lung disease is heterogeneously distributed in the lung. Quantitative scoring tools for studies using chest CT as an end point, and mechanistic studies that seek to better understand the pathogenesis of early cystic fibrosis lung disease, should take account of this differential topographic expression of disease early in life.
Le texte complet de cet article est disponible en PDF.Keyword : CF, CT, FEV1
Plan
Funded by the Cystic Fibrosis Foundation Therapeutics, Inc (Sly040A, Stick090A); the Australian Cystic Fibrosis Research Trust; and the National Health and Medical Research Council (513730), Australia. L.M. is supported by a National Health and Medical Research Council Postgraduate Medical and Dental Scholarship and supplementary scholarships from the University of Western Australia, the Australian Cystic Fibrosis Research Trust, and the Cystic Fibrosis Association of Western Australia. S.S. is a National Health and Medical Research Council Practitioner Fellow. The authors declare no conflicts of interest. |
Vol 163 - N° 1
P. 243 - juillet 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?